disease-modifying therapies

Providers weigh treatment logistics in selecting DMTs for MS patients

Certain clinical attributes of disease-modifying therapies (DMTs), such as safety and the medication’s impact on risk of relapse and disability progression, are considered important by healthcare providers in selecting the appropriate treatment for people with multiple sclerosis (MS), according to a new survey study. However, a study experiment also…

Tysabri best of 6 DMTs to prevent relapses, worse disability in MS

Tysabri (natalizumab) is better than five other disease-modifying therapies (DMTs) at reducing relapses and preventing disability worsening in relapsing-remitting multiple sclerosis (RRMS), according to the findings of a novel simulated clinical trial that directly compared the six treatments. The analysis used mathematical modeling to emulate a clinical trial…

Outcomes better for RRMS patients who start on higher efficacy DMTs

Outcomes are better for people with relapsing-remitting multiple sclerosis (RRMS) initially treated with higher efficacy disease-modifying therapies (DMTs) than for those who begin with lower efficacy DMTs and escalate to more effective treatments as the disease progresses, according to a real-world analysis of patient registry data. Findings also…

Fewer Women With MS Choosing to Stop DMT Use While Pregnant

The use of disease-modifying therapies (DMTs) by pregnant women with multiple sclerosis (MS) significantly increased over the last decade or so, and fewer of them are stopping treatment before giving birth, a single-center study in Italy reported. While most patients (95.1%) discontinued a DMT while pregnant between 2005…

FDA Approval of Ublituximab, Now Briumvi, Is Good News

The new year is bringing a new disease-modifying therapy (DMT) to the multiple sclerosis (MS) arsenal. Shortly after Christmas, the U.S. Food and Drug Administration (FDA) approved Briumvi (ublituximab), which joins a small group of DMTs that aim to halt MS progression by knocking out certain…

Treatments Seen to Account for Largest Part of MS Financial Burden

Medications account for the majority of costs related to managing multiple sclerosis (MS) in Italy, andĀ secondary-progressive MS (SPMS) is associated with higher treatment and healthcare costs than those forĀ relapsing-remitting multiple sclerosis (RRMS), a study looking at real-world data reported. ā€œA bigger healthcare resource consumption was retrieved for…

RRMS Transition to SPMS Fell With Start of DMTs, Swedish Study Finds

The risk of transitioning from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) declined significantly after the introduction of disease-modifying therapies (DMT), according to a large nationwide Swedish study. Data showed that SPMS conversion risk rose by 3% each year before the first generation of…

Progressive MS, Degree of Disability Increase Infection Risk

People with progressive forms of multiple sclerosis (MS) and those with greater MS-related disability have a significantly greater risk of serious infections relative to people without the disease, according to a population-based study in Sweden. Notably, these associations were observed regardless of the use of disease-modifying therapies, many…

More Answers About COVID-19 Vaccines and MS

A little over a year ago, I wrote about whether people with multiple sclerosis (MS) should get a COVID-19 vaccine. I was anxious to be vaccinated as soon as I could, but I was also concerned about how the vaccines would affect someone with MS. Would the side effects…

Pregnancy Poses Challenges to MS Management, Review Study Shows

Women with multiple sclerosis (MS) who receive high-efficacy disease-modifying therapies (DMTs) before conception have a greater risk of relapses and disability progression during pregnancy than those given moderate-efficacy or no DMTs, according to a systematic review of studies. Exclusive breastfeeding for at least two to four months, however,…

Risk of Severe COVID-19 Not Raised by Immunosuppressive DMTs

Exposure to multiple sclerosis (MS) disease-modifying therapies (DMTs), and particularly immunosuppressive DMTs, does not increase the risk of developing a severe form of COVID-19, or of dying from the disease, when adjusting for known risk factors, an Austrian registry-based study found. These findings add to data showing no…

DMTs Underutilized in Younger Patients, Study Indicates

Nearly a third of people with multiple sclerosis (MS) who are younger than 40 are not being treated with disease-modifying treatments (DMTs), even though younger individuals are expected to get the most benefit from DMTs, according to a new study. “DMTs for MS are more frequently used at…